PHENYLEPHRINE BITARTRATE

US Approved OTC

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13NO2.C4H6O6
Molecular Weight	317.2919
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CNC[C@H](O)C1=CC=CC(O)=C1

InChI

InChIKey=NHKOTKKHHYKARN-NDAAPVSOSA-N

InChI=1S/C9H13NO2.C4H6O6/c1-10-6-9(12)7-3-2-4-8(11)5-7;5-1(3(7)8)2(6)4(9)10/h2-5,9-12H,6H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t9-;1-,2-/m01/s1

HIDE SMILES / InChI

Molecular Formula	C9H13NO2
Molecular Weight	167.205
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00388
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-1a adrenergic receptor 66 Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00388	Agonist 2678	55.0 nM [EC50]
Alpha-1b adrenergic receptor 44 Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25813897	Agonist 2678	5.9 nM [EC50]
Alpha-1d adrenergic receptor 36 Target ID: CHEMBL326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831777	Agonist 2678	154.88 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypotension 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf	Primary		Approved 8429	VAZCULEP Approved Use VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Launch Date -5.05007997E11
Eye diseases 25 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Diagnostic		Approved 8429	Phenylephrine Hydrochloride Ophthalmic Solution Approved Use Indicated to dilate the pupil Launch Date -9.7839363E11

C_max

Value	Dose	Analyte	Population
2959 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4492 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1354 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2346 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3900 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
955.8 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.64 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (acute) Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	Disc. AE: Chest pain, Jaw pain... Other AEs: Nervous system disorders, Headache... AEs leading to discontinuation/dose reduction: Chest pain (1 patient) Jaw pain (1 patient) Other AEs: Nervous system disorders (3.6%) Headache (2.7%) Gastrointestinal disorders (8%) Dry mouth (2.7%) Nausea (3.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Other AEs: Eye pain, Blurred vision... Other AEs: Eye pain Blurred vision Photophobia Allergic conjunctivitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
250 ug single, intravenous Recommended Dose: 250 ug Route: intravenous Route: single Dose: 250 ug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf

AEs

AE	Significance	Dose	Population
Ischemic colitis	acute Disc. AE	10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
Chest pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Jaw pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Dry mouth	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Headache	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nausea	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nervous system disorders	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Gastrointestinal disorders	8%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Allergic conjunctivitis		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Blurred vision		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Eye pain		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Photophobia		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP1A2 701

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/16510159/ Page: 10.0	yes

PubMed

Title	Date	PubMed
Troglitazone inhibits alpha1-adrenoceptor-induced DNA synthesis in vascular smooth muscle cells.	1999 Jun 11	10422649
Investigation of the effects of some alkaloidal alpha1-adrenoceptor antagonists on human hyperplastic prostate.	1999 Jun 25	10422796
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.	2000 Apr	10742289
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.	2000 Dec 1	11102496
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.	2000 Feb 1	10655507
Roles of tissue transglutaminase in ethanol-induced inhibition of hepatocyte proliferation and alpha 1-adrenergic signal transduction.	2000 Jul 21	10801782
Presence of NMDA receptor subunits in the male lower urogenital tract.	2000 Jul-Aug	10901443
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.	2000 Jun	10888249
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.	2001 Feb	11160616
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Depletion of phosphatidylinositol 4,5-bisphosphate by activation of phospholipase C-coupled receptors causes slow inhibition but not desensitization of G protein-gated inward rectifier K+ current in atrial myocytes.	2001 Feb 23	11104770
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.	2001 Feb 7	11161004
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.	2001 Jan	11159691
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP.	2001 Jan	11152744
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.	2001 Jan	11133901
Should the angiotensin II antagonists be discontinued before surgery?	2001 Jan	11133595
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.	2001 Jan	11124138
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.	2001 Jan	11124127
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats.	2001 Jan	11123364
alpha-Adrenoceptor stimulation-mediated negative inotropism and enhanced Na(+)/Ca(2+) exchange in mouse ventricle.	2001 Jan	11123227
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.	2001 Jan 15	11164302
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.	2001 Jan 19	11139479
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.	2001 Jan 5	11137871
Insulin-induced relaxation of rat mesenteric artery is mediated by Ca(2+)-activated K(+) channels.	2001 Jan 5	11137870
Evidence of alpha-adrenoceptor-mediated chronotropic action in children.	2001 Jan-Feb	11123125
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.	2001 Mar	11179087
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.	2001 Mar	11179073
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.	2001 Mar	11179035
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.	2001 Mar	11171825

Patents

Sample Use Guides

In Vivo Use Guide

VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.

Route of Administration: Intravenous

In Vitro Use Guide

The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:15:32 UTC 2023` Edited by `admin` on `Sat Dec 16 05:15:32 UTC 2023`
Record UNII	27O3Q5ML57
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHENYLEPHRINE BITARTRATE

Common Name

English

Phenylephrine bitartrate [WHO-DD]

Common Name

English

DUO-MEDIHALER COMPONENT PHENYLEPHRINE BITARTRATE

Common Name

English

R-2-(METHYLAMINO)-1-(3-HYDROXYPHENYL)ETHANOL, HYDROGEN TARTRATE

Common Name

English

PHENYLEPHRINE BITARTRATE [VANDF]

Common Name

English

(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL, HYDROGEN TARTRATE

Common Name

English

PHENYLEPHRINE BITARTRATE [USP MONOGRAPH]

Common Name

English

PHENYLEPHRINE ACID TARTRATE [MART.]

Common Name

English

1-M-HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZYL ALCOHOL, HYDROGEN TARTRATE

Common Name

English

(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL, HYDROGEN TARTRATE

Common Name

English

PHENYLEPHRINE BITARTRATE COMPONENT OF DUO-MEDIHALER

Common Name

English

PHENYLEPHRINE HYDROGEN TARTRATE

Common Name

English

PHENYLEPHRINE BITARTRATE [ORANGE BOOK]

Common Name

English

PHENYLEPHRINE BITARTRATE [USP-RS]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29709